Evidence-based treatment of Alzheimer's disease

Journal of the Korean Medical Association

Volumn 52, Issue 4, 2009, Pages 417-425

  Lee, Dong Woo ^a   Huh, Yoon Seok ^b   Kim, Ki Woong ^b  

^a Inje University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Evidence; Memantine; Pharmacotherapy

Indexed keywords

EID: 79955830493     PISSN: 19758456     EISSN: None     Source Type: Journal    
DOI: 10.5124/jkma.2009.52.4.417     Document Type: Article

References (5)

1. American Psychiatric Association (APA). Practice guideline for the treatment of patients with Alzheimer's disease and other dementias 2nd Edition, 2007: 1-86.
2. Burns A, O'Brien J; BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006; 20: 732-755. (Pubitemid 44622739)
3. California Workgroup on Guidelines for Alzheimer's Disease Management. Guideline for Alzheimer's Disease Management. Final Report, 2008.
4. Fillit HM, Doody RS, Binaso K, Crooks GM, Ferris SH, Farlow MR, Leifer B, Mills C, Minkoff N, Orland B, Reichman WE, Salloway S. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother 2006; 4(S): 9-24.
5. Kim KW. Cognitive enhancers. In: Korean Association for Geriatric Psychiatry. Geriatric Psychiatry, 2nd ed. 2004, Jungangmunwha Co., Seoul, Korea.